Transarterial chemoembolization in a patient with recurrent hepatocellular carcinoma and portal vein thrombosis: a case report and review of the literature.
Primary hepatocellular carcinoma (HCC) accounts for more than 5% of all cancers in the world, and causes between 250,000 and one million deaths globally each year. The incidence of portal vein thrombosis in HCC patients is around 8%. These patients are regarded as unsuitable for chemoembolization, especially if there is portal vein occlusion. The authors describe a patient with HCC and partial portal vein thrombosis who successfully underwent transarterial chemoembolization.
Sikander
Ailawadhi
A
Department of Medicine, Roswell Park Cancer Institute and State University of New York at Buffalo, NY 14263, USA. ailawadhi77@yahoo.com
Sadashiv
Shenoy
S
Ronald
Sham
S
Milind
Javle
J
D000180:Acrylic Resins / Q000008:administration & dosage*; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods; D004317:Doxorubicin / Q000008:administration & dosage*; D005780:Gelatin / Q000008:administration & dosage*; D006689:Hodgkin Disease; D006801:Humans; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000150:complications / Q000628:therapy*; D008297:Male; D008863:Microspheres; D009336:Necrosis; D016609:Neoplasms, Second Primary / Q000628:therapy*; D011169:Portal Vein; D020246:Venous Thrombosis / Q000209:etiology / Q000628:therapy*
D000180:Acrylic Resins; C496735:trisacryl gelatin microspheres; D004317:Doxorubicin; D005780:Gelatin